8-碘-2-萘酚 | 29921-51-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 8-碘-2-萘酚
• 英文名称: 8-iodonaphthalen-2-ol
• 英文别名: 8-iodo-2-naphthol；2-hydroxy-8-iodonaphthalene；7-hydroxy-1-iodonaphthalene；1-iodo-7-hydroxynaphthalene
• CAS: 29921-51-5
• 化学式: C₁₀H₇IO
• 分子量: 270.069
• InChiKey: GGTNBODHPCZTCG-UHFFFAOYSA-N

物化性质

• 沸点：
  376.9±15.0 °C(Predicted)
• 密度：
  1.874±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  8-碘-2-萘酚 在 正丁基锂 、 palladium 10% on activated carbon 、 ammonium acetate 、 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 二氯甲烷 、 丙酮 、 甲苯 为溶剂， -78.0~100.0 ℃ 、413.7 kPa 条件下， 反应 19.25h， 生成 阿戈美拉汀
  参考文献：
  名称：

  A facile synthesis of melatonergic antidepressant agomelatine

  摘要：

  Agomelatine was synthesized from 8-aminonaphthalen-2-ol by diazotization-iodination, formylation, C-C bond formation by nitroaldol and Pd/C hydrogenation of beta-nitrovinylnaphthalene followed by N-acetylation. The route reported employs readily and commercially viable starting materials and reagents, and can potentially be utilized for process synthesis of agomelatine. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.10.077
• 作为产物：
  描述：

  1-氨基-7-萘酚 在 sodium nitrite 、 potassium iodide 作用下， 以 水 为溶剂， 反应 2.0h， 以77%的产率得到8-碘-2-萘酚
  参考文献：
  名称：

  发现用于治疗 2 型糖尿病的新型基于吡啶酮的 EP3 拮抗剂系列

  摘要：

  发现了一系列新的吡啶酮作为有效的 EP3 拮抗剂。由 EP3 结合和功能测定以及 eADME 和 PK 分析指导的优化导致多种化合物具有良好的物理特性、出色的口服生物利用度和干净的体外安全性。化合物13被鉴定为先导化合物，这可以通过在体外 INS 1E β 细胞和体内大鼠 ivGTT 模型中逆转磺胺前列酮诱导的葡萄糖刺激的胰岛素分泌抑制来证明。通过用结构43的吲唑环代替结构13的萘，消除了谷胱甘肽加合倾向。

  DOI：

  10.1021/acsmedchemlett.0c00667

文献信息

• MONNA, a Potent and Selective Blocker for Transmembrane Protein with Unknown Function 16/Anoctamin-1
  作者：Soo-Jin Oh、Seok Jin Hwang、Jonghoon Jung、Kuai Yu、Jeongyeon Kim、Jung Yoon Choi、H. Criss Hartzell、Eun Joo Roh、C. Justin Lee

  DOI：10.1124/mol.113.087502

  日期：2013.11

  Transmembrane protein with unknown function 16/anoctamin-1 (ANO1) is a protein widely expressed in mammalian tissues, and it has the properties of the classic calcium-activated chloride channel (CaCC). This protein has been implicated in numerous major physiological functions. However, the lack of effective and selective blockers has hindered a detailed study of the physiological functions of this channel. In this study, we have developed a potent and selective blocker for endogenous ANO1 in Xenopus laevis oocytes (xANO1) using a drug screening method we previously established ([Oh et al., 2008][1]). We have synthesized a number of anthranilic acid derivatives and have determined the correlation between biological activity and the nature and position of substituents in these derived compounds. A structure-activity relationship revealed novel chemical classes of xANO1 blockers. The derivatives contain a −NO2 group on position 5 of a naphthyl group-substituted anthranilic acid, and they fully blocked xANO1 chloride currents with an IC50 < 10 μ M. The most potent blocker, N -((4-methoxy)-2-naphthyl)-5-nitroanthranilic acid (MONNA), had an IC50 of 0.08 μ M for xANO1. Selectivity tests revealed that other chloride channels such as bestrophin-1, chloride channel protein 2, and cystic fibrosis transmembrane conductance regulator were not appreciably blocked by 10∼30 μ M MONNA. The potent and selective blockers for ANO1 identified here should permit pharmacological dissection of ANO1/CaCC function and serve as potential candidates for drug therapy of related diseases such as hypertension, cystic fibrosis, bronchitis, asthma, and hyperalgesia. [1]: #ref-12

  跨膜蛋白16/anoctamin-1（ANO1）是一种在哺乳动物组织中广泛表达的蛋白质，具有经典钙激活氯通道（CaCC）的特性。这种蛋白质已被认为涉及许多主要的生理功能。然而，缺乏有效且选择性的阻断剂阻碍了对该通道生理功能的详细研究。在本研究中，我们利用先前建立的药物筛选方法（Oh等，2008），开发了一种对非洲爪蟾卵母细胞中内源性ANO1（xANO1）具有强效和选择性的阻断剂。我们合成了许多邻氨基苯甲酸衍生物，并确定了这些衍生物中的生物活性与取代基性质和位置之间的关联。从结构-活性关系中发现了一系列新的xANO1阻断剂化学类别。这些衍生物在萘基取代的邻氨基苯甲酸的5位含有一个−NO2基团，能完全阻断xANO1氯电流，IC50 < 10 μM。最强效的阻断剂，N -((4-甲氧基)-2-萘基)-5-硝基邻氨基苯甲酸（MONNA），对xANO1的IC50为0.08 μM。选择性测试表明，其他氯通道如bestrophin-1、氯通道蛋白2和囊性纤维化跨膜传导调节因子在10～30 μM MONNA下未被明显阻断。本研究识别出的对ANO1具有强效和选择性的阻断剂应能允许对ANO1/CaCC功能进行药理学解析，并作为治疗高血压、囊性纤维化、支气管炎、哮喘和痛觉过敏等相关疾病的潜在药物候选。
• PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS
  申请人：Janssen Pharmaceutica NV

  公开号：US20190047959A1

  公开（公告）日：2019-02-14

  The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

  本发明涉及吡啶-2-酮衍生物，包含它们的药物组合物以及它们作为EP3受体的拮抗剂的使用，用于治疗例如受损的口服葡萄糖耐量、空腹血糖升高、2型糖尿病、综合征X（也称为代谢综合征）及其相关疾病和并发症。
• PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS
  申请人：Janssen Pharmaceutica NV

  公开号：US20190047961A1

  公开（公告）日：2019-02-14

  The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

  本发明涉及吡啶-2-酮衍生物，包含它们的药物组合物以及它们作为EP3受体的拮抗剂的使用，用于治疗例如受损的口服葡萄糖耐量，空腹血糖升高，2型糖尿病，综合征X（也称为代谢综合征）以及与之相关的疾病和并发症。
• Synthesis and Photochromism of Novel Pyridyl-Substituted Naphthopyrans
  作者：Orlando D. C. C. de Azevedo、Paul I. P. Elliott、Christopher D. Gabbutt、B. Mark Heron、Kyle J. Lord、Christopher Pullen

  DOI：10.1021/acs.joc.0c01296

  日期：2020.8.21

  Multitarget synthetic strategies to access novel photochromic 3H-naphtho[2,1-b]pyrans decorated with pyridyl units are described. The new pyridyl-substituted 3H-naphtho[2,1-b]pyrans display good photochromic properties with reversible generation of photomerocyanines, which exhibit mainly orange/red hues. Photochromic parameters including photocolorability and persistence of color vary tremendously

  描述了多目标合成策略，以访问新型的吡啶基单元修饰的光致变色3 H-萘[ 2,1- b ]吡喃。新的吡啶基取代的3 H-萘[ 2,1 - b ]吡喃具有良好的光致变色特性，可逆生成的光金属花青素主要表现为橙色/红色。光致变色参数（包括光致变色性和颜色的持久性）在萘并吡喃核的结构修饰上有很大差异。
• Inhibitors of prenyl-protein transferase
  申请人：Merck & Co., Inc.

  公开号：US06441017B1

  公开（公告）日：2002-08-27

  The present invention is directed to macrocyclic compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemothera-peutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.

  本发明涉及抑制萜基-蛋白转移酶（FTase）和致癌基因蛋白Ras的大环化合物。该发明还涉及含有本发明化合物的化疗组合物以及抑制萜基-蛋白转移酶和致癌基因蛋白Ras的方法。